Mental Health

Mental Health

Angelini's commitment

The burden of mental health conditions is on the rise globally and major depression, bipolar mood disorder and schizophrenia are among the 10 leading causes of disability worldwide. Mental disorders continue to impose enormous social and economic burden on the community, leading to premature mortality and affecting functioning and quality of life of both patients and their families.
Only in Europe, annually, nearly 40% of the population is diagnosed or report a mental health condition. Therefore, mental healthcare is a priority that requires full multi-stakeholders’ commitment. (Wittchen, H.U., et al. (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 21, 655–679.)

Angelini, over the past 50 years, has gained international recognition for its substantial efforts to improve the management of patients with mental health conditions and to fight mental health stigma.
The company has played a pioneering role in the development of antidepressants and mood stabilisers and has now embraced the challenge to support the design of new paradigms in patient care, from innovative treatments to societal commitment. Indeed, mental health remains a neglected area and Angelini wants to contribute to change this fact not only through drug R&D, but also by supporting high-quality projects such as HEADWAY 2020. This project, undertaken at the end of 2017 in collaboration with the European House–Ambrosetti, aims to design a new roadmap for mental health that will provide a global overview on the mental health context in Europe by focusing on social as well as on economic dimensions. The final objective is to advance today's paradigm of the management and treatment of mental illness so that the social and health-care systems in each country can guarantee adequate and effective care pathways and assistance and, at the same time, promote better quality of life for patients and encourage legitimate social inclusion. This is also expected to have a strong and positive impact on families.

Mental health Key Facts

Angelini S.p.a.
Viale Amelia 70, 00181 Roma
P.IVA 01258691003 e C.F. Numero di iscrizione registro imprese: 03907010585
Ufficio del registro delle imprese: Roma
Capitale: € 165.000.000 I.V.

© Angelini S.p.a. - Tutti i diritti riservati